GlassScriptPhysician profile
Michelle Jones-Moon
NPI 1750943288
$5,156.14
in general payments reported to CMS, 2019-2025
38 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $233 · 2023: $1,691 · 2024: $1,437 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,922.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $774.35 | 2022-2025 | |
| Lilly USA, LLC | $579.97 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $475.91 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $375.60 | 2023-2025 | |
| Astellas Pharma US INC | $357.92 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $303.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $289.87 | 2022-2025 | |
| Lundbeck LLC | $289.25 | 2023-2025 | Vyepti, Rexulti |
| Dexcom, INC. | $165.48 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $154.15 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $142.92 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.15 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $109.32 | 2023-2025 | Injectafer |
| Axsome Therapeutics, INC. | $106.08 | 2024-2025 | Symbravo, Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $98.47 | 2022-2025 | Trintellix |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $86.32 | 2023-2025 | Spravato |
| Scilex Pharmaceuticals INC. | $79.32 | 2023 | Ztlido |
| Novartis Pharmaceuticals Corporation | $68.37 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.47 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Phathom Pharmaceuticals, INC. | $58.23 | 2024-2025 | Voquezna |
| Amgen INC. | $47.52 | 2023-2024 | Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $44.39 | 2023-2024 | Camzyos, Eliquis |
| Abbott Laboratories | $43.99 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Medtronic, INC. | $39.21 | 2025 | Intellis Adaptivestim |
| Idorsia Pharmaceuticals US INC | $33.70 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $30.02 | 2023 | |
| Eisai INC. | $26.77 | 2024 | |
| Vbi Vaccine (Delaware) INC. | $24.40 | 2023 | Prehevbrio |
| Vanda Pharmaceuticals INC. | $21.60 | 2024 | Hetlioz, Fanapt |
| Ultragenyx Pharmaceutical INC. | $21.32 | 2023 | |
| Corium, LLC | $19.48 | 2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $17.37 | 2022 | |
| Tris Pharma INC | $16.71 | 2023 | Dyanavel Xr |
| Nevro Corp. | $16.69 | 2024 | Senza |
| Antares Pharma, INC. | $14.95 | 2024 | Xyosted |
| Inspire Medical Systems, INC. | $14.66 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $14.58 | 2022 | |
| Esperion Therapeutics, INC. | $14.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Jones-Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.